Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
53M
-
Number of holders
-
187
-
Total 13F shares, excl. options
-
31.4M
-
Shares change
-
+894K
-
Total reported value, excl. options
-
$3.98B
-
Value change
-
+$124M
-
Put/Call ratio
-
0.72
-
Number of buys
-
95
-
Number of sells
-
-111
-
Price
-
$126.93
Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q2 2021
247 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q2 2021.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 187 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.4M shares
of 53M outstanding shares and own 59.15% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (4.49M shares), WELLINGTON MANAGEMENT GROUP LLP (3.85M shares), VANGUARD GROUP INC (2.86M shares), BlackRock Inc. (2.51M shares), JPMORGAN CHASE & CO (1.77M shares), Alua Capital Management LP (1.24M shares), KPS Global Asset Management UK Ltd (1.13M shares), 683 Capital Management, LLC (911K shares), MORGAN STANLEY (753K shares), and Antipodean Advisors LLC (639K shares).
This table shows the top 187 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.